Detail of "58795-03-2"

Reference

Fundamental and clinical studies on PC-904

Fundamental and clinical studies on PC-904. Sawae, Yoshiro (Sch. Health Sci., Kyushu Univ., Fukuoka, Japan). Chemotherapy (Tokyo), 26(Suppl. 2), 363-70 (Japanese) 1978. CODEN: NKRZAZ. ISSN: 0369-4682. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 3 Of the 115 strains isolated from various clin. materials employed, strains sensitive to PC-904 (I) [58795-03-2] (min. inhibitory concn. < 12.5 mg/mL) included 7 strains of Staphylococcus aureus (33% of those tested), 2 strains of Streptococcus faecalis (50%), 1 strain of Enterobactor (5%), and 11 strains of Pseudomonas (52%). When 1 g of I was administered by drip infusion or one-shot i.v. infusion, the peak serum concn. was 113.6 mg/mL and 242 mg/mL, resp. The half-life of I in serum was 40 and 30 min and the serum concn. was 4.3 and 7.0 mg/mL at 6 h after drip infusion and one-shot infusion, resp. When 1 g of I was administered by drip infusion and one-shot i.v. infusion, the urinary excretion rate for 6 h was 13.7% and 13.0%, resp. The clin. effects of I on 5 respiratory tract infections, 3 urinary tract infections and 3 other infections at 1-3 g/day for 2-38 days was considered good in 7 cases, fair in 2 and poor in 2 cases. I was effective against infections caused by Pseudomonas and Streptococcus pneumoniae.

PC-904, a new semisynthetic penicillin

PC-904, a new semisynthetic penicillin. Bodey, Gerald P.; Weaver, Suzanne; Pan, Theresa (Univ. Texas Syst. Cancer Cent., M. D. Anderson Hosp. and Tumor Inst., Houston, Tex., USA). Antimicrob. Agents Chemother., 13(1), 14-18 (English) 1978. CODEN: AMACCQ. ISSN: 0066-4804. DOCUMENT TYPE: Journal CA Section: 3 (Biochemical Interactions) PC-904 (I) [58795-03-2], at a concn. of 1.56 mg/mL, inhibited 100% of isolates of Proteus mirabilis, 89% of Pseudomonas aeruginosa, 67% of Escherichia coli, and 45% of Enterobacter secies. At a concn. of 12.5 mg/mL I inhibited 75% of Klebsiella spp. and 67% of Serratia marcescens. I failed to inhibit the growth of gram-neg. bacilli when large inocula were used. Some differences were noted when organisms were tested in different media or at different H+ concns. I was more active than mezlocillin, azlocillin, ticarcillin, carbenicillin, and amoxicillin against Escherichia coli, Klebsiella species, and Pseudomonas aeruginosa.